1-10 of 10
Daniel A. Laheru
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma

Lei Zheng, Ding Ding, Barish H. Edil, Carol Judkins, Jennifer N. Durham, Dwayne L. Thomas, II, Katherine M. Bever, Guanglan Mo, Sara E. Solt, Jessica A. Hoare, Raka Bhattacharya, Qingfeng Zhu, Arsen Osipov, Beth Onner, Katrina A. Purtell, Hongyan Cai, Rose Parkinson, Amy Hacker-Prietz, Joseph M. Herman, Dung T. Le, Nilofer S. Azad, Ana M.C. De Jesus-Acosta, Alex B. Blair, Victoria Kim, Kevin C. Soares, Lindsey Manos, John L. Cameron, Martin A. Makary, Matthew J. Weiss, Richard D. Schulick, Jin He, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Elizabeth Sugar, Elizabeth M. Jaffee, Daniel A. Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1278–1286.
https://doi.org/10.1158/1078-0432.CCR-20-2974
Published: 01 March 2021
View article titled, Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma
Open the PDF for Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose M. Parkinson, Jennifer N. Durham, Beth Onners, Anna K. Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang-Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5129–5139.
https://doi.org/10.1158/1078-0432.CCR-20-1025
Published: 01 October 2020
View article titled, A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Open the PDF for A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis

Arsen Osipov, Su Jin Lim, Aleksandra Popovic, Nilofer S. Azad, Daniel A. Laheru, Lei Zheng, Elizabeth M. Jaffee, Hao Wang, Mark Yarchoan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4842–4851.
https://doi.org/10.1158/1078-0432.CCR-20-0458
Published: 15 September 2020
View article titled, Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
Open the PDF for Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis in another window
Includes: Supplementary data
Journal Articles

Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

Takahiro Tsujikawa, Todd Crocenzi, Jennifer N. Durham, Elizabeth A. Sugar, Annie A. Wu, Beth Onners, Julie M. Nauroth, Robert A. Anders, Elana J. Fertig, Daniel A. Laheru, Kim Reiss, Robert H. Vonderheide, Andrew H. Ko, Margaret A. Tempero, George A. Fisher, Michael Considine, Ludmila Danilova, Dirk G. Brockstedt, Lisa M. Coussens, Elizabeth M. Jaffee, Dung T. Le
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3578–3588.
https://doi.org/10.1158/1078-0432.CCR-19-3978
Published: 15 July 2020
View article titled, Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Open the PDF for Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

Vincent P. Groot, Stacy Mosier, Ammar A. Javed, Jonathan A. Teinor, Georgios Gemenetzis, Ding Ding, Lisa M. Haley, Jun Yu, Richard A. Burkhart, Alina Hasanain, Marija Debeljak, Hirohiko Kamiyama, Amol Narang, Daniel A. Laheru, Lei Zheng, Ming-Tseh Lin, Christopher D. Gocke, Elliot K. Fishman, Ralph H. Hruban, Michael G. Goggins, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Victor E. Velculescu, Jin He, Christopher L. Wolfgang, James R. Eshleman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4973–4984.
https://doi.org/10.1158/1078-0432.CCR-19-0197
Published: 15 August 2019
View article titled, Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Open the PDF for Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Strategies for Increasing Pancreatic Tumor Immunogenicity

Burles A. Johnson, III, Mark Yarchoan, Valerie Lee, Daniel A. Laheru, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (7): 1656–1669.
https://doi.org/10.1158/1078-0432.CCR-16-2318
Published: 02 April 2017
View article titled, Strategies for Increasing Pancreatic Tumor Immunogenicity
Open the PDF for Strategies for Increasing Pancreatic Tumor Immunogenicity in another window
Journal Articles

Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors

Shinichi Yachida, Catherine M. White, Yoshiki Naito, Yi Zhong, Jacqueline A. Brosnan, Anne M. Macgregor-Das, Richard A. Morgan, Tyler Saunders, Daniel A. Laheru, Joseph M. Herman, Ralph H. Hruban, Alison P. Klein, Siân Jones, Victor Velculescu, Christopher L. Wolfgang, Christine A. Iacobuzio-Donahue
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6339–6347.
https://doi.org/10.1158/1078-0432.CCR-12-1215
Published: 14 November 2012
View article titled, Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
Open the PDF for Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors in another window
Includes: Supplementary data
Journal Articles

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

Dung T. Le, Dirk G. Brockstedt, Ran Nir-Paz, Johannes Hampl, Shruti Mathur, John Nemunaitis, Daniel H. Sterman, Raffit Hassan, Eric Lutz, Bentley Moyer, Martin Giedlin, Jana-Lynn Louis, Elizabeth A. Sugar, Alice Pons, Andrea L. Cox, Jordana Levine, Aimee Luck Murphy, Peter Illei, Thomas W. Dubensky, Jr, Joseph E. Eiden, Elizabeth M. Jaffee, Daniel A. Laheru
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 858–868.
https://doi.org/10.1158/1078-0432.CCR-11-2121
Published: 31 January 2012
View article titled, A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Open the PDF for A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774): Early Termination Due To Increased Toxicities

Wells A. Messersmith, Daniel A. Laheru, Neil N. Senzer, Ross C. Donehower, Paula Grouleff, Theresa Rogers, Sean K. Kelley, David A. Ramies, Bert L. Lum, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6522–6527.
https://doi.org/10.1158/1078-0432.CCR-04-0746
Published: 08 October 2004
View article titled, Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774): <subtitle>Early Termination Due To Increased Toxicities</subtitle>
Open the PDF for Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774): <subtitle>Early Termination Due To Increased Toxicities</subtitle> in another window